Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 4/20 | 1.00 |
| ▸ | MPI | P34949 | 1/20 | 0.48 |
| ▸ | PGK1 | P00558 | 1/20 | 0.47 |
| ▸ | PGK2 | P07205 | 1/20 | 0.47 |
| ▸ | TPI1 | P60174 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16798059 | 1.00 | PGD (1.00) | PGDMPIPGK1PGK2TPI1 | |
| SCHEMBL16798058 | 1.00 | PGD (1.00) | PGDMPIPGK1PGK2TPI1 | |
| SCHEMBL6910642 | 0.89 | PGD (0.80) | PGDMPIPGK1PGK2TPI1 | |
| SCHEMBL15653993 | 0.87 | PGD (0.77) | PGDMPIPGK1PGK2TPI1 | |
| SCHEMBL15694600 | 0.87 | PGD (0.77) | PGDMPIPGK1PGK2TPI1 | |
| SCHEMBL15694950 | 0.83 | PGD (0.71) | PGDMPIPGK1PGK2TPI1 | |
| SCHEMBL4317467 | 0.81 | PGD (0.69) | PGDMPIPGK1PGK2TPI1 | |
| SCHEMBL420471 | 0.78 | PGD (1.00) | PGDMPIPGK1PGK2 | |
| SCHEMBL20475915 | 0.78 | PGD (1.00) | PGDMPIPGK1PGK2 | |
| SCHEMBL20475914 | 0.78 | PGD (1.00) | PGDMPIPGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100028334-A1 | COMPOSITIONS AND METHODS TO POTENTIATE COLISTIN ACTIVITY | TRUSTEES OF BOSTON UNIVERSITY (US) | 2010-02-04 | — | — | US | claimed |
| WO-2008076806-A9 | COMPOSITIONS AND METHODS TO POTENTIATE COLISTIN ACTIVITY | UNIV BOSTON (US) | 2008-08-07 | — | — | WO | claimed |
| WO-2008076806-A2 | COMPOSITIONS AND METHODS TO POTENTIATE COLISTIN ACTIVITY | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-06-26 | — | — | WO | claimed |
| WO-2026099341-A1 | BIOCONTAINMENT OF UNWANTED ENGINEERED CELLS USING NON-NATURAL AMINO ACIDS | SNIPR BIOME APS (DK) | 2026-05-15 | — | — | WO | disclosed |
| EP-4735462-A1 | COMPOUNDS AND USES THEREFOR | GLYCOSYNNOVATIONS PTY LTD (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-12564596-B2 | Agents and methods for modulating pathogen activity | GRIFFITH UNIVERSITY (AU) | 2026-03-03 | — | — | US | disclosed |
| EP-4659014-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | President And Fellows Of Harvard College (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250195501-A1 | CELL ENTRY-MODULATING AGENTS AND USES THEREFOR | GRIFFITH UNIVERSITY (AU) | 2025-06-19 | — | — | US | disclosed |
| WO-2025000059-A1 | COMPOUNDS AND USES THEREFOR | Glycosynnovations Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| CN-118986994-A | Agents and methods for modulating pathogen activity | 格里菲斯大学 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024197225-A1 | REDOX ACTIVE ANTIFOULING COATINGS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-09-26 | — | — | WO | disclosed |
| EP-2238157-A2 | ENGINEERED BACTERIOPHAGES AS ADJUVANTS FOR ANTIMICROBIAL AGENTS AND COMPOSITIONS AND METHODS OF USE THEREOF | Trustees of Boston University (US) | 2010-10-13 | — | — | EP | disclosed |
| US-20100028334-A1 | COMPOSITIONS AND METHODS TO POTENTIATE COLISTIN ACTIVITY | TRUSTEES OF BOSTON UNIVERSITY (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009108406-A2 | ENGINEERED BACTERIOPHAGES AS ADJUVANTS FOR ANTIMICROBIAL AGENTS AND COMPOSITIONS AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-09-03 | — | — | WO | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009026328-A2 | METHODS OF DELIVERY OF AGENTS TO LEUKOCYTES AND ENDOTHELIAL CELLS | IMMUNE DISEASE INSTITUTE, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| WO-2008076806-A9 | COMPOSITIONS AND METHODS TO POTENTIATE COLISTIN ACTIVITY | UNIV BOSTON (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008076806-A2 | COMPOSITIONS AND METHODS TO POTENTIATE COLISTIN ACTIVITY | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195501-A1 | CELL ENTRY-MODULATING AGENTS AND USES THEREFOR | ACE2, ACE, TMPRSS2 | PGD 4431/4885MPI 736/4885PGK1 3602/4885 |
| US-12564596-B2 | Agents and methods for modulating pathogen activity | C3AR1, HTR3A, CHRM3 | PGD 3333/4885MPI 2796/4885PGK1 4498/4885 |
| US-20100028334-A1 | COMPOSITIONS AND METHODS TO POTENTIATE COLISTIN ACTIVITY | VIP, C1QBP, CALCA | PGD 1243/4885MPI 2165/4885PGK1 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.